Abbott Laboratories 2013 Annual Report Download - page 56

Download and view the complete annual report

Please find page 56 of the 2013 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 76

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76

ABBOTT 2013 ANNUAL REPORT
54
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The following segment information has been prepared in
accordance with the internal accounting policies of Abbott,
as described above, and are not presented in accordance with
generally accepted accounting principles applied to the
consolidated financial statements.
Net Sales to
(in millions) External Customers (a) Operating Earnings (a)
2013 2012 2011 2013 2012 2011
Established
Pharmaceuticals $ 4,974 $  5,121 $ 5,355 $1,182 $1,237 $1,254
Nutritionals 6,740 6,461 5,989 1,263 1,020 792
Diagnostics 4,545 4,292 4,126 1,008 825 794
Vascular 3,012 3,071 3,333 962 1,020 1,111
Total Reportable
Segments 19,271 18,945 18,803 $4,415 $4,102 $3,951
Other 2,577 2,549 2,604
Total $21,848 $21,494 $21,407
(a) Net sales and operating earnings were unfavorably affected by the relatively stronger
U.S. dollar in 2013 and 2012 and were favorably affected by the relatively weaker
U.S. dollar in 2011.
(in millions) 2013 2012 2011
Total Reportable Segment Assets $11,178 $11,136 $11,905
Cash, investments and restricted funds (c) 8,217 15,448 8,476
Current deferred income taxes (c) 2,528 2,986 2,701
Non‑reportable segments 1,181 1,167 1,148
Goodwill and intangible assets (c) 15,507 24,362 25,695
All other (c) 4,342 12,136 10,352
Total Assets $42,953 $67,235 $60,277
(c) In 2012 and 2011, the reported amounts include assets associated with the businesses
transferred to AbbVie as part of the separation.
(in millions) 2013 2012 2011
Total Reportable Segment
Operating Earnings $4,415 $ 4,102 $ 3,951
Corporate functions and
benefit plans costs (514) (598) (529)
Non‑reportable segments 423 443 457
Net interest expense (90) (288) (294)
Net loss on extinguishment of debt — (1,351) —
Share‑based compensation (262) (284) (256)
Amortization of intangible assets (791) (795) (884)
Other, net (b) (660) (924) (1,209)
Earnings from Continuing Operations
before Taxes $2,521 $  305 $ 1,236
(b) Other, net includes: charges for cost reduction initiatives of approximately $350 million
in 2013 and $430 million in 2012; and charges of $240 million in 2011 for cost reduction
initiatives and integration.
Net Sales to
(in millions) External Customers (d) Long‑term Assets (e)
2013 2012 2011 2013 2012 2011
United States $ 6,269 $ 6,349 $ 6,302 $ 7,884 $15,244 $15,867
Japan 1,442 1,723 1,726 902 1,169 1,225
Germany 1,070 984 1,058 1,040 6,173 5,909
The Netherlands 960 1,107 1,204 560 532 462
China 1,083 859 625 356 259 127
India 922 919 917 3,080 3,467 3,160
Brazil 470 448 470 216 200 186
Switzerland 792 693 591 1,117 1,214 1,045
Canada 734 753 652 368 352 237
Italy 726 719 761 100 222 229
France 680 667 781 213 220 214
Russia 525 485 427 30 37 21
Spain 413 417 447 326 314 293
United Kingdom 479 497 475 1,380 1,345 1,273
All Other Countries 5,283 4,874 4,971 6,133 5,164 6,260
Consolidated $21,848 $21,494 $21,407 $23,705 $35,912 $36,508
(d) Sales by country are based on the country that sold the product.
(e) Amounts reported in 2012 and 2011 include assets associated with businesses transferred
to AbbVie as part of the separation.
Additions to
(in millions) Depreciation Long‑term Assets Total Assets
2013 2012 2011 2013 2012 2011 2013 2012 2011
Established Pharmaceuticals $ 84 $  156 $  169 $  128 $  237 $  122 $ 2,637 $ 2,805 $ 4,348
Nutritionals 190 175 167 340 428 205 3,518 3,211 2,939
Diagnostics 368 295 313 394 349 394 3,312 3,286 3,218
Vascular 122 76 99 62 69 109 1,711 1,834 1,400
Total Reportable Segments 764 702 748 924 1,083 830 $11,178 $11,136 $11,905
Other 164 661 647 982 902 845
Total $928 $1,363 $1,395 $1,906 $1,985 $1,675